EUPRAXIA PHARMACEUTICALS INC. financial statements
Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data EUPRAXIA PHARMACEUTICALS INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
FY2025
Revenue
0
0
0
Research and development
13.6
20.4
16.1
21.3
General and administrative
3.99
7.48
10.9
17.1
Operating expenses
17.6
27.8
27
38.4
Interest expense
0.98
1.17
0.6
0
Interest income
0.43
0.86
1.16
1.41
Other non-operating income
-1.37
-1.08
1.26
-0.15
Pre-tax income
-19
-28.9
-25.7
-38.6
Income tax
0
0.04
0
0.02
Income from continuing operations
-28.2
-25.9
-41.1
Net income to minority interests
-0.5
-0.75
-0.24
-0.03
Net income
-18.5
-28.2
-25.5
-38.6
EPS, basic
-0.96
-1.17
-0.76
-1.03
EPS, diluted
-0.96
-1.17
-0.76
-1.03
Shares, basic (weighted)
19.3
24.1
33.9
40
Shares, diluted (weighted)
19.3
24.1
33.9
40
Balance sheet
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
18.3
19.3
33.1
80.6
Receivables
0.15
0.26
0.72
Other current assets
0.24
0.27
1.11
3.86
Total current assets
18.6
19.8
34.4
85.1
Property, plant and equipment
0.44
0.41
0.36
0.83
Lease right-of-use assets
0.09
0.05
0.07
0.15
Total assets
19.1
20.3
34.9
86.2
Accounts payable
1.81
1.29
0.38
0.94
Total current liabilities
3.06
19.4
3.1
5.63
Lease liabilities
0.05
0
0
0.08
Total liabilities
11.9
19.4
3.1
5.7
Paid-in capital
16.9
17.5
20.5
28.5
Retained earnings
-77.3
-106
-131
-170
Other comprehensive income
-2.79
-2.71
-4.16
-2.04
Shareholders' equity
7.79
2.22
33.4
82
Minority interests
-0.58
-1.32
-1.57
-1.6
Total equity
7.21
0.89
31.8
80.4
Total liabilities and equity
19.1
20.3
34.9
86.2
Shares outstanding
21.6
27.3
35.6
51.9
Cash flow statement
FY2023
FY2023
FY2024
FY2025
Net income
-19
-29
-25.7
-38.6
Depreciation and amortization
0.15
0.16
0.17
0.24
Stock-based compensation
1.43
1.41
3.22
8.76
Deferred income tax
0
0
0
0
Change in receivables
0.23
-0.1
-0.1
-0.43
Change in payables
1.32
0.58
-0.71
2.36
Cash from operations
-14.4
-20.7
-30
-28.6
Purchases of investments
-3.27
Cash from investing
9.83
-0.07
-0.08
-0.59
Debt repaid
-0.07
-0.08
-0.06
0
Stock issued
10.6
15.9
22.9
73.9
Cash from financing
10.8
21.1
45.8
76.1
Net change in cash
6.24
0.26
15.7
46.9
Interest paid
0.33
0.6
0.39
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $8.01 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-66.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-63.7%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
145.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
119.2%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
146.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
65.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
17.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
27.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
15.1x
Current assets / current liabilities.
Quick ratio
14.4x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
14.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$1.03
Net income per basic share, as reported (split-adjusted).
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.71
Cash from operations / diluted weighted shares.
Book value per share
$1.58
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
6.43x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
6.43x
Market cap / tangible book value, when positive.
Earnings yield
-7.3%
Net income / market cap (the inverse of P/E).
What was EUPRAXIA PHARMACEUTICALS INC.'s revenue in fiscal 2025?
EUPRAXIA PHARMACEUTICALS INC. reported revenue of $0.0 for fiscal 2025.
Was EUPRAXIA PHARMACEUTICALS INC. profitable in fiscal 2025?
No. It reported a net loss of $38.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.